Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.39
-2.5200-2.97%
Post-market: 82.640.2500+0.30%18:18 EDT
Volume:1.60M
Turnover:130.74M
Market Cap:11.61B
PE:-36.08
High:83.76
Open:83.13
Low:80.75
Close:84.91
52wk High:95.49
52wk Low:22.73
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.57
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:24.93
PE(LYR):-6,757.16

Loading ...

Arrowhead Pharmaceuticals Receives Tga Approval of Redemplo® (Plozasiran) in Australia, Expanding Global Access for Patients With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
May 01

Arrowhead Pharmaceuticals - Phase 3 Study Shows Redemplo Reduces Triglycerides by Median 80% From Baseline

THOMSON REUTERS
·
May 01

JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target

MT Newswires Live
·
May 01

Arrowhead Pharmaceuticals : JP Morgan Initiates Coverage With Overweight Rating; Target Price $88

THOMSON REUTERS
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153%, and institutional views are bullish

Earnings Agent
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153.09%, and institutional views are bullish

Earnings Agent
·
May 01

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.
·
Apr 28

Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts

TIPRANKS
·
Apr 25

Arrowhead CFO Daniel Joseph Apel disposes of common shares worth $921,276

Reuters
·
Apr 25

Arrowhead CMO James Hamilton disposes of 10,000 shares worth $750,000

Reuters
·
Apr 25

Arrowhead says CHMP backs EU approval of REDEMPLO for familial chylomicronemia syndrome

Reuters
·
Apr 24

Arrowhead Pharmaceuticals - Receives Positive Chmp Opinion for Redemplo (Plozasiran) in Fcs in Europe

THOMSON REUTERS
·
Apr 24

Arrowhead Pharmaceuticals - European Commission Decision on Redemplo Marketing Authorization Expected in Q2 2026

THOMSON REUTERS
·
Apr 24

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. -- Barrons.com

Dow Jones
·
Apr 21

Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga_recent_news
·
Apr 21

Arrowhead Pharmaceuticals Raised to Overweight From Equal-Weight by Morgan Stanley

Dow Jones
·
Apr 21

Arrowhead Pharmaceuticals Inc : Morgan Stanley Raises to Overweight From Equal-Weight

THOMSON REUTERS
·
Apr 21

Arrowhead Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $100.00 From $78.00

THOMSON REUTERS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Apr 21

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
Apr 21